Skip to main content

Grafa News and Videos — Page 1643

Latest

Grafa

Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028

Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company applying genetic insights to the development of precision medicines, reported its fourth-quarter and full-year 2025 financial results on Wednesday, March 25, 2026.

Read more: Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028
Grafa

ProMIS Neurosciences advances Alzheimer’s pipeline following landmark $75.5M financing

ProMIS Neurosciences (NASDAQ:PMN), a biotechnology company developing antibody therapeutics for neurodegenerative diseases, reported its full-year 2025 financial results and provided a comprehensive corporate update on March 25, 2026.

Read more: ProMIS Neurosciences advances Alzheimer’s pipeline following landmark $75.5M financing
Grafa

KalVista reports $49.1M in EKTERLY revenue as commercial pivot drives strategic transition

KalVista Pharmaceuticals (NASDAQ:KALV) today reported financial results for the abbreviated fiscal period ended December 31, 2025, marking the company’s formal transition from a clinical-stage developer to a commercial-stage biopharmaceutical entity.

Read more: KalVista reports $49.1M in EKTERLY revenue as commercial pivot drives strategic transition
Grafa
Defence

Lockheed Martin and Department of War to quadruple PrSM production following combat debut

Lockheed Martin (NYSE:LMT) and the U.S. Department of War (DoW) announced a landmark framework agreement on March 25, 2026, to dramatically accelerate the manufacturing of Precision Strike Missiles (PrSM).

Read more: Lockheed Martin and Department of War to quadruple PrSM production following combat debut

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift